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Estrogen receptor (ER)Abstract Background and purpose: Oestrogen receptor (ER) and HER (human epidermal growth
factor receptor) family signaling pathways are fundamental to guide treatment and determine prog-
nosis. Categorizing breast cancer tumors as ER and Her-2 positive or negative is usually performed
by immunohistochemistry (IHC), however the technique lacks standardization in handling tissues,
staining techniques, and scoring systems.
The current study aimed to compare the conventional IHC and the RT-PCR techniques in assessing
the ER-alpha status in breast cancer. It also validates the application of RT-PCR technique in
detecting the Her-2/neu status.
Subjects and methods: The study included 40 patients with IDC (NOS) (invasive ductal carcinoma;
not otherwise speciﬁed). Breast tissue specimens were collected at the time of the elective surgery.
Specimens were subjected to routine pathological examinations. ER alpha and PR receptor
status; assessed by immunohistochemical staining. RNA was extracted, reverse transcribed, and
ampliﬁed by PCR using ER alpha and HER-2 speciﬁc primers. Relative expression was detected
276 E. El-Abd et al.by comparing the expression in normal and tumor samples relative to the housekeeping (b-actin)
gene expression.
Results: IHC and RT-PCR techniques showed great discrepancies in detecting ER alpha status
which might be due to the presence of ER alpha variants. RT-PCR showed higher sensitivity
(72.7%) and accuracy (57.6%) than IHC in detecting ER alpha status. Gene expression of HER-
2 was detected (by RT-PCR) in 67.5% (27/40) with overexpression in 25% (10/40) of the cases.
Conclusion: IHC and RT-PCR must be combined for more informative results regarding the ER
alpha and HER-2 status. Further studies are mandatory to evaluate the efﬁcacy of anti-estrogens
on ER alpha variant expression.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Breast cancer is the most common form of cancer among
women and the second cause of death in childbearing period.
The average age of presentation is 10 years lesser than in the
west.1 In Egypt, breast cancer represents 35.1% of all female
cancers with 80–90% of cases of advanced stages (III or IV)
at presentation.2
Breast cancer is characterized by genetic heterogeneity
which makes its diagnosis and treatment challenging.3 Despite
having similar histological appearance, individual breast
tumors can exhibit tremendous variations in clinical presenta-
tion, disease aggressiveness, and treatment response in differ-
ent patient and ethnic populations.4 Therefore, breast cancer
is currently regarded as a heterogeneous disease that has been
classiﬁed into various molecular subtypes according to the
gene expression proﬁle of ER, PR, and Her-2/neu including:
basal cell-like or triple negative (ER-, PR-, and HER2-),
Her-2/neu (ER-, PR-, and HER2+), luminal A (ER + and/
or PR+, HER2-), luminal B (ER+ and/or PR+,
HER2+), and normal breast like.5–8 It is evident now that
the breast cancer heterogeneity is more complicated than
thought before. Recently, Mosoyan et al.9 isolated ﬁve cell
lines (Her2, ER, CK8/18, CD44, and CD24) from a single
patient’s primary breast cancer tissue. The isolated cells
showed variable tumorigenic and metastatic potential when
tested in immunocompromised nude mice.
ER is a member of a family of nuclear receptors. It func-
tions as transcriptional regulator that mediates the biological
responses to the sex hormone estrogen which is essential for
reproduction, cardiovascular, skeletal and nervous systems.10
Currently there are two different forms of estrogen receptors;
a and b receptors that are co-expressed in many cell types.
Each encoded by separate genes (ESR1 and ESR2) that are
present on different chromosomes. ESR1gene is located on q
arm of chromosome 6, while ESR2 gene is located on q arm
of chromosome 14.11–13 ERa and ERb show signiﬁcant overall
sequence homology with the greatest homology (close to
100%) in their DNA binding domains, and both are composed
of seven domains. Hormone activated estrogen receptors form
homo-[ERa (aa) or ERb (bb)] or heterodimers [ERab (ab)]
ERa.10 ER-a gene (ESR1) comprises eight exons of more than
140 Kb separated by seven introns of  40 kb. Each exon
encodes a certain region of the protein.14,15
Researchers have identiﬁed 20 ER alpha splice variants in
human breast cancers.16,17 The most abundant variants are
created by splicing deletions in one or more exons.18–22Patterns of splice variant expression differ between tumors
and are quite heterogeneous. Splice variants could potentially
affect the evaluation of ER status, but this has not been proven
yet.23 The generation of human ER alpha mRNA transcripts is
a complex process that involves at least seven different pro-
moters and exhibits cell line-dependent promoter usage.24
Most ER alpha variants differ in the 50 untranslated region
and result in the expression of the full-length 66-kDa form
of ER alpha.24 Among others, 46-kDa isoforms of ER alpha
(ER alpha 46) generated from an internal ATG start codon,
lacks exon 1 and consequently the N-terminal AF-1
region.25–27 Wang and co-workers identiﬁed and cloned a 36-
kDa isoform of ER alpha (named ER alpha 36). ER alpha
36 is generated from a promoter located in the ﬁrst intron of
the ER alpha gene and it lacks both of the two transcriptional
activation domains AF-1 and AF-2.28,29
In some estrogen-dependent cells and tissues, ER might
directly activate G-protein-coupled receptors and/or heterodi-
meric Her (human epidermal growth factor) receptors, result-
ing in downstream activation of MAPK and PI3K
pathways.30 In turn, p38 (protein 38), a member of the MAPK
family, is capable of phosphorylating and activating ER in a
ligand-independent manner. This cross-talk activation of ER
results in the loss of inhibitory effects of tamoxifen.31,32
Her-2 (human epidermal growth factor receptor-2; also
known as c-erb-B2, HER-2/neu, p185, CD340) proto-onco-
gene is located at the long arm of human chromosome 17
(17q21–q22).33 It is part of a family of genes that play roles
in regulating cell growth. The protein it makes is a tyrosine
kinase (TK) growth factor receptor expressed by a number
of normal tissues and probably has a role in normal cell func-
tion, regulating growth and proliferation.
The full length 4.6 Kb Her-2/neu transcript encodes a
185 kDa transmembrane glycoprotein receptor with intrinsic
tyrosine kinase (TK) activity. It contains an N-terminal extra-
cellular domain (ECD), a single transmembrane helix, a TK
domain, and an intracellular regulatory domain. The ECD is
600 residues long and contains four (I–IV) domains includ-
ing a site of potential ligand binding between domains I and
III. The ECD can undergo proteolytic cleavage in the juxta-
membrane region that releases soluble Her-2/neu ECD (90–
110 kD).34 The intracellular domain is 500 residues long
and consists of a TK domain and an intracellular regulatory
domain. The TK domain contains the enzymatic sequences
necessary for TK activity. The intracellular domain also con-
tains multiple tyrosine residues which serve as substrates for
other TK receptors.30
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product (100 KDa) consisting of the entire ECD rather than
the full-length protein.35 The 50 region (2.1 Kb) of the trun-
cated transcript (2.3 Kb) is identical to that of the full length.
However, the 30 end diverges revealing an exonic extension
with in frame stop codon and a poly (A) addition site. Thus
the truncated transcript differs from the full length in 20 amino
acids on the C-terminal.
Her-2/neu gene is ampliﬁed in 20–25% of primary breast
tumors and has been associated with poor prognosis.36
Increases in Her-2/neu at the DNA, RNA, and protein levels
have been similarly prognostic for poor outcomes in primary
breast cancer.37
The use of molecular classiﬁcation of breast cancer is lim-
ited in many countries including Egypt. IHC is cheap and
widely available. However the reproducibility of ER, PR,
and HER2 status is a major issue in daily practice and in clin-
ical investigation. Therefore, the current study was designed to
evaluate the accuracy and speciﬁcity of IHC and RT-PCR in
detecting ER alpha status in IDC (NOS). It also validates
the use of RT-PCR in detecting Her-2/neu status.
2. Subjects and methods
The study included 40 patients (sample size was based on pre-
viously published work) with IDC (NOS) randomly selected
from cases presented to the Cancer Management and Research
Department of medical research institute (MRI) (from Febru-
ary 2007 to August 2009). Tumor samples were subjected to
pathology assessment and only IDC (NOS) cases were
included according to simple random sampling without
replacement; lottery method. Clinical diagnosis, treatment,
and clinical follow up were performed as described by El-
Abd et al.38 All subjects were recruited according to the ethical
rules approved by the ethics committee of the MRI based on
Belmont report.39 Tumor and normal tissue specimens (far
from tumor site to serve as self-controls) were collected during
the elective surgery and stored at 80 C until use.
2.1. Pathological investigations
Hematoxylin (Genzyme, England) and Eosin (Chematec, UK)
(H&E) stained breast sections (3–4 lm) were examined by the
pathologist to determine tumor type, size, grade, stage,40 and
number of the involved lymph nodes. ER alpha, total
progesterone receptor (PR) and Her’s-2/neu status were
detected by IHC using streptavidin–biotin peroxidase labeled
speciﬁc monoclonal antibodies (Lab Vision, USA)41,42 and scored
according to ASCO-CAP test guideline recommendations (http://
www.cap.org/apps/docs/committees/immunohistochemistry/
summary_of_recommendations.pdf).
2.2. Molecular investigations
Total RNA was isolated from breast tissue samples using EZ-
10 Spin Column Total RNA Minipreps Super Kit (Bio Basic
Inc, Canada) according to the manufacturer’s instructions.
The quantiﬁcation and purity of the prepared RNA was exam-
ined using the spectrophotometer (UNICAM; Helios Delta,
England) at wavelengths of 260 nm and 280 nm and by aga-
rose gel electrophoresis. Full-length cDNA prepared fromtotal RNA (5 lg) using revert aidHminus ﬁrst strand cDNA
synthesis kit (MBI Fermentas, Germany) and random hexa-
mer primer according to the manufacturer’s protocol. Fourth
of the reaction was then ampliﬁed using 2· PCR Master Mix
(MBI Fermentas, Germany) and the sequence speciﬁc primers
for ERa (50-ATG AGA GCT GCC AAC CTT-30 and 50-AAC
AAG GCA CTG ACC ATC T -30) or Her-2 neu (50-CCT CTG
ACG TCC ATC ATC TC-30 and 50-ATC TTC TGC TGC
CGT CGC TT-30) (Metabion International AG, Deutschland).
To verify the integrity of the extracted total RNA, all samples
were additionally assayed for human b-actin (50-CAC TGT
GTT GGC GTA CAG GT-30 & 50-TCA TCA CCA TTG
GCA ATG AG-30) (Metabion International AG, Deutsch-
land). Positive and negative controls were included as
appropriate. The Ampliﬁcation protocol has an initial dena-
turation for 5–8 min at 95 C, 35 cycles; 30 s at 95 C, 90 s at
60 C for ERa or 56 C for Her-2 neu and b-actin, and 90 s
at 72 C; plus a ﬁnal elongation for 7–10 min at 72 C. The
ampliﬁed products (ERa; 104 bp, Her-2 neu; 98 bp, and b-
actin; 164) were separated by agarose gel electrophoresis
(3%), stained with ethidium bromide, and visualized by UV.
The relative expression level of ER alpha and Her-2/neu (rela-
tive to b-actin expression ratio in both normal and tumor sam-
ples) was quantiﬁed using the Scion image program for
Windows.
2.3. Statistical analysis
Data analysis was performed using SPSS version 11.5. Nor-
mality tests showed abnormally distributed continuous vari-
ables (K.S < 0.05) except age. Thus, description of
abnormally distributed variables was done using the median
and range. For age, description was done using the mean
and standard deviation (M± SD). Comparison of continuous
variables was done using the Mann–Whitney U test if it was
between two groups while Kruskal–Wallis X2 was used if it
was between several groups. Comparison of the age between
groups was performed using the student t-test. Regarding
qualitative variables, description was done using the percent-
age and comparison between groups was performed through
the Fishers exact test (in case of 2 · 2 tables) or the Monte
Carlo test (in case of rxc tables) due to invalid X2. The
survival curve was constructed using Kaplan–Meier plots
and Wilcoxon–Gehan statistics.3. Results
3.1. Study population
Age of patients ranged between 20 to 74 years (minimum to
maximum; Mean ± SD: 50.7 ± 9.8); menstrual status: 55%
postmenopausal, 35% premenopausal, and 10% perimeno-
pausal. Patients were followed up clinically for 76 months.
During this period, three (3/40; 7.5%) patients had metastasis
and 33 (33/40; 82.5%) patients died (Table 1 and Fig. 1).
3.2. ER alpha status
The clinicopathological characteristics of patients with IDC
(NOS) are summarized in Table 1. Although great discrepancy
Table 1 Clinicopathological characteristics of patients with
IDC (NOS).
Parameter Number (%)
ERa (as detected by IHC)*
Negative 11 (27.5)
Positive 29 (72.5)
Weak (+) 13 (32.5)
Moderate (++) 11 (27.5)
Strong (+++) 5 (12.5)
ERa (as detected by RT-PCR)
Negative 12 (30)
Positive 28 (70)
PR (as detected by IHC)*
Negative 11 (27.5)
Positive 29 (72.5)
Weak (+) 12 (30)
Moderate (++) 12 (30)
Strong (+++) 5 (12.5)
Her-2/neu gene expression (as detected by RT-PCR)
Negative 13 (32.5)
Positive 27 (67.5)
LNM
Negative (0) 10 (25)
Positive 30 (75)
I (1–3) 9 (22.5)
2 (4–9) 11 (27.5)
3 (P10) 10 (25)
Tumor size (cm)
Minimum–Maximum 1–10
<2 2 (5)
2–5 31 (77.5)
>5 6 (15)
Unknown (excision biopsy) 1 (2.5)
Tumor stage
Tx 1 (2.5)
I 4 (10)
II 11 (27.5)
III 22 (55)
IV 2 (5)
Histological grade
I 1 (2.5)
II 26 (65)
III 13 (32.5)
Clinical outcome
Non-metastatic 37 (92.5)
Metastatic 3 (7.5)
Local 1 (2.5)
Distant 2 (5)
Survival 7 (17.5)
Death 33 (82.5)
* Scoring according to CAP-ASCO guidelines.
Figure 1 Overall survival curve for breast cancer patients.
Table 2 ERa as detected by both RT-PCR and IHC
techniques.
ERa protein (IHC) ERa gene expression (RT-PCR)
Positive Negative Total
Positive 21 8 29
Negative 7 4 11
Total 28 12 40
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40) of cases were positive by both techniques (IHC and RT-
PCR) (Table 2, Figs. 2 and 3). Similarly 10% (4/40) were neg-
ative for ER alpha status by both techniques (Table 2, Figs. 2
and 3) i.e. the complete match in the results of both IHC and
RT-PCR techniques was observed in 62.5% (21/40: positive
cases; 4/40: negative cases) and the discrepancy between the
two techniques was detected in 37.5% (15/40) of cases.Fifth of cases (8/40; 20%) were ER alpha positive by IHC
only (positive by IHC but negative by RT-PCR) (Table 2) and
7 cases (7/40; 17.5%) were ER alpha negative by IHC only
(negative by IHC but positive by RT-PCR) (Table 2).
No signiﬁcant difference was observed between ER alpha
status and any of the tumor grade (p= 0.453), size
(p= 0.745), stage (p= 0.268), LNM (p= 0.339), or the num-
ber of the involved LNs (p= 0.168).
3.3. PR status
PR was positive in 72.5% of cases as detected by IHC (Fig. 4).
PR and ER status differed in one patient only regarding the
score of positivity (Table 1).
3.4. Her-2/neu status
Her-2/neu status is not a routine in the pathological protocols
in Egypt. It is only examined in ER alpha negative cases that
can afford Herceptin (trastuzumab) and/or other tyrosine
kinase inhibitor treatment regimens (Figs. 3 and 5). Her-2/
neu gene expression was detected (by RT-PCR) in 67.5%
(27/40) of tumor specimens (Table 1). Overexpression (relative
to b-actin) was detected in 25% (10/40) of the cases.
No signiﬁcant difference was observed between Her-2 sta-
tus and any of the tumor grade (p= 0.714), size (p= 0.571),
stage (p= 0.160), LNM (p= 0.693), the number of the
involved LNs (p= 0.889), or ER alpha status (p= 0.354).
ERα 104 bp
Her-2/neu 98 bp
β-actin 164 bp
Figure 3 Gel electrophoresis of ERa, Her-2/neu, and b-actin
RT-PCR products.
A
B
Figure 2 Nuclear staining of ERa by IHC (A: Negative; B:
strong positive +++; ·400).
A
B
Figure 4 Nuclear staining of PR (total) by IHC (A: Negative; B:
strong positive +++; ·400).
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The current study documents the importance of combining
IHC and RT-PCR techniques in detecting ER alpha status
at the time of diagnosis and treatment decision.
4.1. Study population
The median age of patients with breast carcinoma in this study
(50 years) is almost similar to that detected by Omar et al.1among Egyptian population (30–60 years; median age is
46 years) which is one decade younger than the corresponding
age in Europe and North America. Tumor size, grade, histo-
logical type, LNM (lymph node metastasis), number of the
involved LNs (lymph nodes) and their distribution are also
in accordance with disease presentation in Egypt.1
4.2. ER alpha Status; controversies between IHC and RT-PCR
results
The discrepancies in ER alpha status might indicate technical
limitations and/or presence of ER alpha variants. Although
the superiority of the predictive value of ER-immunohisto-
chemistry (ER-IHC) over ligand-binding techniques has been
established to everyone’s satisfaction, there remains the con-
troversial issue of immunohistochemical results.43 Several
studies reported controversial results between the IHC and
RT-PCR techniques.44–47
Although every step in both techniques can affect the
results48; and thus would account for such variations; other
effectors are not ruled out. Taking into consideration that
IHC detects the protein and RT-PCR detects the mRNA,
one possible cause for discrepancy may be the differential
stability between human ER mRNA and protein; variation
in translation efﬁciency or the rate of mRNA and protein
AB
Figure 5 Her-2 neu as detected by IHC (cell membranous
staining; A: Negative; B: strong positive +++; ·1000).
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life, which was determined to be approximately 5 h in MCF-
7 cell line after actinomycin D treatment.49 Ligand binding,
in addition to altering the conformation of the receptor, has
been shown to inﬂuence the stability of the receptor. In partic-
ular, it has been shown that in the absence of ligand, the half-
life of ERa is about 4–5 h, whereas estradiol binding acceler-
ates receptor degradation, reducing its half-life to 3–4 h.49–53
4.2.1. RT-PCR negative/ IHC positive cases
Several investigators identiﬁed a number of estrogen receptor
(ESR) mRNA variants (truncated transcripts, exon deleted
transcripts, and larger than wild-type ER mRNA products
resulting from nucleotide insertions) in a variety of cancer cell
lines and tumors including tissues from human breast can-
cers.16,54,55 In 35 ESR-positive tumors,56 a common proﬁle
of variant ESR transcripts was present, with all tumors con-
taining the exon 2-deleted and exon 7-deleted ESR variants,
94% containing the exon 4-deleted ESR variant, and 83% con-
taining the exon 5-deleted ESR variant. Since the primers in
our study were designed against a 104 fragment of exon four,
variants that lack this exon will not be detected by RT-PCR
technique. Several of the variant transcripts generated by an
exon skipping mechanism of the primary ER-a pre-mRNAretain the same reading frame as the full-length transcript,
and the corresponding variant proteins have been detected
in vivo and in vitro.22,57–60 Receptors with ‘outlaw’ function,
including both a dominant-positive receptor which was trans-
criptionally active in the absence of estrogen, and a dominant-
negative receptor, which was itself transcriptionally inactive
but prevented the action of normal estrogen receptor, were
discovered using a yeast transactivation assay and open
reading frame analysis.17,21 The monoclonal antibody SP1
used in our study in detecting ER alpha protein using the
IHC technique is designed against 18 merit peptide
(SLQKYYITGEAEGFPATV) representing the C-terminal of
human ERa protein. Thus, the IHC technique can detect
variant products that lack exon-4 provided that the resulting
protein has the same afﬁnity toward the antibody, same
conformational determinants, and the same recognition
epitope(s).4.2.2. RT-PCR positive/IHC negative cases
ERa 36 variant was detected in colorectal cancers and their
matched normal colorectal tissues.61 In contrast to full-length
ERa 66 functional domains, ERa 36 lacks both transactivation
domains AF-1 and AF-2 but retains its DNA-binding, ligand-
binding domains, partial dimerization and three potential
myristoylation sites. It also possesses an extra, unique 27-
amino acids’ domain to replace the last 5 helixes (helix 8–12)
of the 12 helixes in the ERa 66. Providing that ERa 36 variant
is dominant in some tumor samples, it would not be detectable
by SP1 antibody due to the change in helix 8–12 but will be
detectable by RT-PCR.
Due to such controversial issues of IHC and RT-PCR
results, it is suggested to combine both techniques in detecting
ERa status for breast cancer patients. It is also preferred to fol-
low these recommendations:
1. Proper sample transfer, storage, and processing according
to the subsequent technique (IHC or RT-PCR or
in situ. . .etc.).
2. Report should include the sample location, type of anti-
body or primer, use of standard chemicals and detection
kits.
3. Refer to a reference laboratory as a ﬁnal evaluator.
4.3. Her-2/neu status
Her-2/neu mRNA was detected with variable intensities
(degree of positivity) in 67.5% (27/40) and over expression
was detected in 10/40 (25%) of cases. Only three cases (3/40;
7.5%) had results using the IHC technique since it is not a rou-
tine pathological investigation in Egypt. A result of RT-PCR
depends only on the presence (positive) or absence (negative)
of bands while both negative (0) and positive one (+) scores
in IHC are considered negative. If we apply the same scoring
system of the IHC (on protein level) on the RT-PCR (on
RNA level) relative expression results, the percentage of posi-
tive cases (25%) [0: 13 (32.5%); +: 17 (42.5%); ++: 5
(12.5%); +++: 5 (12.5%)] will be within the acceptable levels
in the Arab countries (22%). 62 It is obvious that results may
vary according to the detection technique, molecular detection
level, age, race, and tumor stage. 63,64 The RNA expression
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Her2 assessment65 that require small amounts of tumor tissues
and deliver both semi- and possible quantitative estimates of
the Her2 RNA. Further comparative studies to evaluate the
usefulness of these techniques; in both diagnosis and progno-
sis; are required.
No signiﬁcant correlation was observed between expression
of Her-2/neu and any of breast cancer prognostic variables
(tumor size, histological grade, lymph node metastasis) or
age or menopausal status. These results are in accordance with
the research result of Ellsworth et al.66
5. Conclusion
We can conclude that it would be advantageous to combine
the IHC and RT-PCR techniques in detecting ER alpha status
to avoid the false negative results especially for triple negative
(TN) patients (ER-, PR-, and HER-2) who usually have poor
clinical outcome and no speciﬁc systemic treatment. Further
studies would be mandatory to estimate the inﬂuence of anti-
estrogen drugs on ER alpha variants to improve the clinical
response in breast cancer patients.
Her-2/neu was detected by RT-PCR, and found in 70% of
our cases. Her-2 represents an ideal therapeutic target because
it is accessible; as a cell surface receptor; to treatment with che-
motherapy. Recently, herceptin, a monoclonal antibody
known as trastzumab, has shown to be effective than chemo-
therapy alone. Therefore, testing Her-2/neu in breast cancer
at the time of primary diagnosis is of a prime importance.
Thus, a routine examination of Her-2/neu using both RT-
PCR and IHC techniques is highly recommended for ensuring
proper classiﬁcation of the patients’ Her-2/neu status and tai-
loring therapy.Conﬂict of interest
The authors declare that they have no conﬂict of interest.References
1. Omar S, Khaled H, Gaafar R, Zekry AR, Eissa S, Elkhatib O.
Breast cancer in Egypt: a review of disease presentation and
detection strategies. East Mediterr Health J 2003;9(3):448–63.
2. El-Attar IA. Cancer databases in the Arab World. Ethn Dis
2005;15(1 Suppl 1), S 1-3-4.
3. Ihemelandu CU, Leffall Jr LD, Dewitty RL, Naab TJ, Mezghebe
KH, Makambi KH, et al. Molecular breast cancer subtypes in
premenopausal and postmenopausal African American women:
age-speciﬁc prevalence and survival. J Surg Res
2007;143(1):109–18.
4. Wiencke JK. Impact of race/ethnicity on molecular pathways in
human cancer. Nat Rev Cancer 2004;4(1):79–84.
5. Cancer Genome Atlas Network. Comprehensive molecular por-
traits of human breast tumours. Nature 2012;490(7418):61–70.
6. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H,
et al. Gene expression patterns of breast carcinomas distinguish
tumor subclasses with clinical implications. Proc Natl Acad Sci
2001;98:10869–74.
7. Almendro V, Fuster G. Heterogeneity of breast cancer: etiology
and clinical relevance. Clin Transl Oncol 2011;13(11):767–73.
8. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, et al. The
clinicopathologic characteristics and prognostic signiﬁcance oftriple-negativity in node-negative breast cancer. BMC Cancer
2008;8:307.
9. Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, et al.
Multiple breast cancer cell-lines derived from a single tumor differ
in their molecular characteristics and tumorigenic potential. PLoS
One 2013;8(1):e55145.
10. Li X, Huang J, Yi P, Bambara RA, Hilf R, Muyan M. Single-
chain estrogen receptors (ERs) reveal that the ER alpha/beta
heterodimer emulates functions of the ER alpha dimer in genomic
estrogen signaling pathways. Mol Cell Biol 2004;24(17):7681–94.
11. Gosden JR, Middleton PG, Rout D. Localization of the human
oestrogen receptor gene to chromosome 6q24–q27 by in situ
hybridization. Cytogenet Cell Genet 1986;143(3–4):218–20.
12. Candelaria NR, Liu K, Lin CY. Estrogen receptor alpha:
Molecular mechanisms and emerging insights. J Cell Biochem
2013. http://dx.doi.org/10.1002/jcb.24584 Epub ahead of print.
13. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P,
et al. Human oestrogen receptor cDNA: sequence, expression and
homology to v-erb-A. Nature 1986;320(6058):134–9.
14. Greene GL, Gilna P, Waterﬁeld M, Baker A, Hort Y, Shine J.
Sequence and expression of human estrogen receptor complemen-
tary DNA. Science 1986;231(4742):1150–4.
15. Kuiper GG, Gustafsson JA. The novel estrogen receptor-beta
subtype: potential role in the cell- and promoter-speciﬁc actions of
estrogens and anti-estrogens. FEBS Lett 1997;410(1):87–90.
16. McGuire WL, Chamness GC, Fuqua SA. Estrogen receptor
variants in clinical breast cancer. Mol Endocrinol
1991;5(11):1571–7.
17. Poola I, Abraham J, Baldwin K. Identiﬁcation of ten exon
deleted ERb mRNAs in human ovary, breast, uterus and bone
tissues: alternate splicing pattern of estrogen receptor ß mRNA is
distinct from that of estrogen receptor alpha. FEBS Lett
2002;516(1–3):133–8.
18. Murphy LC. Estrogen receptor variants in human breast cancer.
Mol Cell Endocrinol 1990;74(2), C83-C6.
19. Fuqa SA, Allred DC, Auchus RJ. Expression of estrogen receptor
variants. J Cell Biochem Suppl 1993;17G:194–7.
20. Encarnacion CA, Fuqua SA. Estrogen receptor variants in breast
cancer. Cancer Treat Res 1994;71:97–109.
21. Pfeffer U. Estrogen receptor mRNA variants. Do they have a
physiological role? Ann N Y Acad Sci 1996;784:304–13.
22. Zhang Q-X, Hilsenbeck SG, Fuqua SAW, Borg A. Multiple
splicing variants of the estrogen receptor are present in
individual human breast tumors. J Steroid Biochem Mol Biol
1996;59(3–4):251–60.
23. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer:
current issues and keys to increasing testing accuracy. Adv Anat
Pathol 2005;12(1):10–9.
24. Reid G, Denger S, Kos M, Gannon F. Human estrogen receptor-
alpha: regulation by synthesis, modiﬁcation and degradation. Cell
Mol Life Sci 2002;59(5):821–31.
25. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G,
et al. Identiﬁcation of a new isoform of the human estrogen
receptor-alpha (hER-alpha) that is encoded by distinct transcripts
and that is able to repress hER-alpha activation function 1.
EMBO J 2000;19(17):4688–700.
26. Li L, Haynes MP, Bender JR. Plasma membrane localization and
function of the estrogen receptor alpha variant (ER46) in human
endothelial cells. Proc Natl Acad Sci USA 2003;100(8):4807–12.
27. Kim KH, Bender JR. Rapid estrogen receptor-mediated signaling:
why is the endothelium so special? Sci STKE 2005;288:Pe28.
28. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF.
Identiﬁcation, cloning, expression of human estrogen receptor
alpha36, a novel variant of human estrogen receptor-alpha66.
Biochem Biophys Res Commun 2005;336(4):1023–7.
29. Ascenzi P, Bocedi A, Marino M. Structure–function relationship
of estrogen receptor alpha and beta: impact on human health.Mol
Aspects Med 2006;27(4):299–402.
282 E. El-Abd et al.30. Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic
and clinical complexities of HER2. Clin Breast Cancer
2008;8(5):392–401.
31. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D,
Coronado E, et al. Estrogen-dependent tamoxifen-resistant
tumorigenic growth of MCF-7 cells transfected with HER2/neu.
Breast Cancer Res Treat 1992;24(2):85–95.
32. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred
DC, et al. Molecular changes in tamoxifen resistant breast cancer:
relationship between estrogen receptor, HER-2, and p38 mitogen-
activated protein kinase. J Clin Oncol 2005;23(11):2469–76.
33. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath
J, et al. Tyrosine kinase receptor with extensive homology to EGF
receptor shares chromosomal location with NEU oncogene.
Science 1985;230(4730):1132–9.
34. Molina MA, Sa´ez R, Ramsey EE, Garcia-Barchino MJ, Rojo F,
Evans AJ, et al. NH (2)-terminal truncated HER-2 protein but
not full-length receptor is associated with nodal metastasis in
human breast cancer. Clin Cancer Res 2002;8(2):347–53.
35. Scott GK, Robles R, Park JW, Montgomery PA, Daniel J,
Holmes WE, et al. A truncated intracellular HER2/neu receptor
produced by alternative RNA processing affects growth of human
carcinoma cells. Mol Cell Biol 1993;13(4):2247–57.
36. Owens MA, Horten BC, Da Silva MM. HER2 ampliﬁcation ratios
by ﬂuorescence in situ hybridization and correlation with immu-
nohistochemistry in a cohort of 6556 breast cancer tissues. Clin
Breast Cancer 2004;5(1):63–9.
37. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith
DE, et al. Studies of the HER-2/neu protooncogene in human
breast and ovarian cancer. Science 1989;244(4905):707–12.
38. El-Abd E, Hassan A, Faied W, Zaki S, Sobhi A, El-Swedy S, et al.
Clinical relevance of HIF-1 alpha, Cox-2, leptin, and prolactin as
hypoxic markers in breast cancer. AJC 2012;11(4):237–46.
39. The Belmont Report. Ethical Principles and Guidelines for the
Protection of Human Subjects of Research. The National Com-
mission for the Protection of Human Subjects of Biomedical and
Behavioral Research. April 18, 1979. http://www.hhs.gov/ohrp/
policy/belmont.html (accessed 28.01.14).
40. Singletary SE, Connolly JL. Breast cancer staging: working with
the sixth edition of the AJCC Cancer Staging Manual. CA Cancer
J Clin 2006;56:37–47.
41. Saad A, Sheta M, Sobhi A, Aly E, El-Abd E. Clinical and
pathological assessment of sentinel lymph node micrometastasis in
breast cancer using RT-PCR. J Egypt Soc Path 2005;25(1):81–7.
42. Abd EL-Moneim N, Ebid S, Kazem A, Saad A, Mousa S, EL-
ABD E, et al. The role of angiogenesis assessment in the prognosis
of breast carcinoma and in the evaluation of the therapeutic effect
of ‘‘shark care’’ drug as an angiogenesis inhibitor. Turkish J cancer
2008;38(3):123–34.
43. Nadji M. Quantitative Immunohistochemistry of estrogen recep-
tor in breast cancer. ‘‘much ado about nothing!’’. Appl Immuno-
histochem Mol Morphol 2008;16(2):105–7.
44. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and
predictive factors in breast cancer by immunohistochemical
analysis. Mod Pathol 1998;11(2):155–68.
45. Layﬁeld LJ, Gupta D, Mooney EE. Assessment of tissue estrogen
and progesterone receptor levels. Breast J 2000;6(3):189–96.
46. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD.
Reliability of immunohistochemical demonstration of oestrogen
receptors in routine practice: interlaboratory variance in the
sensitivity of detection and evaluation of scoring systems. J Clin
Pathol 2000;53(2):125–30.
47. Gown AM. Current issues in ER and HER2 testing by IHC in
breast cancer. Mod Pathol 2008;21(Suppl 2):S8–S15.
48. Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J. The
effects of ﬁxation, processing and evaluation criteria on immuno-
histochemical detection of hormone receptors in breast cancer.
Breast cancer 2007;14(2):182–8.49. Wijayaratne AL, McDonnell DP. The human estrogen receptor-
alpha is a ubiquitinated protein whose stability is affected
differentially by agonists, antagonists, and selective estrogen
receptor modulators. J Biol Chem 2001;276(38):35684–92.
50. Eckert RL, Mullick A, Rorke EA, Katzenellenbogen BS. Estrogen
receptor synthesis and turnover in MCF-7 breast cancer cells
measured by a density shift technique. Endocrinology
1984;114(2):629–37.
51. Monsma Jr FJ, Katzenellenbogen BS, Miller MA, Ziegler YS,
Katzenellenbogen JA. Characterization of the estrogen receptor
and its dynamics in MCF-7 human breast cancer cells using a
covalently attaching antiestrogen. Endocrinology
1984;115(1):143–53.
52. Scholl S, Lippman ME. The estrogen receptor in MCF-7 cells:
evidence from dense amino acid labeling for rapid turnover and a
dimeric model of activated nuclear receptor. Endocrinology
1984;115(4):1295–301.
53. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI
164,384 reduces cellular estrogen receptor content by increasing its
turnover. Proc Natl Acad Sci USA 1992;89(9):4037–41.
54. Varayoud J, Ramos JG, Monje L, Bosquiazzo V, Mun˜oz-de-Toro
EH, Luque EH. The estrogen receptor UTR3 mRNA splicing
variant is differentially regulated by estrogen and progesterone in
the rat uterus. J Endocrinol 2005;186(1):51–60.
55. Hopp TA, Fuqua SA. Estrogen receptor variants. J Mammary
Gland Biol Neoplasia 1998;3(1):73–83.
56. Balleine RL, Hunt SM, Clarke CL. Coexpression of alternatively
spliced estrogen and progesterone receptor transcripts in human
breast cancer. J Clin Endocr Metab 1999;84(4):1370–7.
57. Leygue ER, Watson PH, Murphy LC. Estrogen receptor variants
in normal human mammary tissue. J Natl Cancer Inst
1996;88(5):284–90.
58. Gallacchi P, Schoumacher F, Eppenberger-Castori S, Von Lan-
denberg EM, Kueng W, Eppenberger U, et al. Increased expres-
sion of estrogen receptor exon-5-deletion variant in relapse tissues
of human breast cancer. Int J Cancer 1998;79(1):44–8.
59. Daffada AA, Johnston SR, Smith IE, Detre S, King N, Dowsett
M. Exon 5 deletion variant estrogen receptor messenger RNA
expression in relation to tamoxifen resistance and progesterone
receptor/pS2 status in human breast cancer. Cancer Res
1995;55(2):288–93.
60. Koehorst SG, Cox JJ, Donker GH, Lopes da Silva S, Burbach JP,
Thijssen JH, et al. Functional analysis of an alternatively spliced
estrogen receptor lacking exon 4 isolated from MCF-7 breast
cancer cells and meningioma tissue. Mol Cell Endocrinol
1994;101(1-2):237–45.
61. Jiang H, Teng R, Wang Q, Zhang X, Wang H, Wang Z, et al.
Transcriptional analysis of estrogen receptor alpha variant
mRNAs in colorectal cancers and their matched normal colorectal
tissues. J Steroid Biochem Mol Biol 2008;112(1–3):20–4.
62. Runnak MA, Hazha MA, Hemin HA, Wasan AA, Rekawt RM,
Michael HD. A population-based study of Kurdish breast cancer
in northern Iraq: hormone receptor and HER2 status. A compar-
ison with Arabic women and United States SEER data. BMC
Womens Health 2012;12:16.
63. Ismail MF, Aly MS, Khaled HM, Mohamed HM. Detection of
HER-2/neu, c-myc ampliﬁcation and p53 inactivation by FISH in
Egyptian patients with breast cancer. Ger, Med Sci 2009;7:Doc03.
64. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash
R. Population-based estimate of the prevalence of HER-2 positive
breast cancer tumors for early stage patients in the US. Cancer
Invest 2010;28(9):963–8.
65. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al.
The Her-2/neu gene and protein in breast cancer 2003: biomarker
and target of therapy. Oncologist 2003;8(4):307–25.
66. Ellsworth RE, Ellsworth DL, Patney HL, Deyarmin B, Love B,
Hooke JA, et al. Ampliﬁcation of HER2 is a marker for global
genomic instability. BMC Cancer 2008;8:297.
